secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0000950170-22-016454
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q2 loss $23.1M; cash $223.6M extends runway to 2025
------------------------------------------------------------------------

- Collaboration revenue $1.4M vs $0 in Q2 2021; R&D spend $18.9M, G&A $5.5M.
- Cash and securities $223.6M as of June 30, extended cash runway through 2025 via portfolio prioritization.
- BDC-1001 monotherapy/combination dose-escalation data and RP2D expected H2 2022.
- BDC-2034 discontinued due to off-target toxicity; focus on BDC-1001, BDC-3042, and next-gen ISAC.
- BDC-3042 IND-enabling studies underway; clinical start on track for 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022016454/0000950170-22-016454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022016454/bolt-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer